Get the Stockscreener App
1.32
1.13%
-0.01
Lexicon Pharmaceuticals Inc stock is traded at $1.32, with a volume of 2.16M.
It is down -1.13% in the last 24 hours and up +16.37% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.33
Open:
$1.31
24h Volume:
2.16M
Relative Volume:
0.69
Market Cap:
$479.69M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.65
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
+7.79%
1M Performance:
+16.37%
6M Performance:
+268.24%
1Y Performance:
-12.91%
1-Day Range:
$1.27
$1.335
1-Week Range:
$1.16
$1.34
52-Week Range:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.32 | 483.32M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
379.45 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.03 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.79 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
710.36 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.00 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia
Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com
Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus
Lexicon pharmaceuticals announces update on submission of additional data to U.S. FDA - MarketScreener
Lexicon expects delay in FDA feedback on additional data for its diabetes drug - Reuters
Lexicon (LXRX) Seeks FDA Feedback on Zynquista with New Data Sub - GuruFocus
Lexicon reports FDA's decision to extend review period for Zynquista - Seeking Alpha
Lexicon Pharmaceuticals Provides Update on Zynquista NDA Resubmission Following FDA Feedback - Quiver Quantitative
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - The Manila Times
FDA Extends Review of Breakthrough Diabetes Drug Zynquista: What Lexicon's New Data Shows - Stock Titan
Nasdaq Moves: Whats the MACD signal for Lexicon Pharmaceuticals IncStop Loss & Verified High Yield Trade Plans - خودرو بانک
Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Market Review: What is the target price for Lexicon Pharmaceuticals Inc stockM&A Rumor & Entry Point Strategy Guides - خودرو بانک
Guidance Update: Can Lexicon Pharmaceuticals Inc. reach all time highs this yearMarket Performance Summary & Daily Technical Forecast Reports - خودرو بانک
Geopolitics Watch: Is Lexicon Pharmaceuticals Inc a defensive stockPortfolio Gains Report & Risk Controlled Swing Alerts - خودرو بانک
What makes Lexicon Pharmaceuticals Inc. stock attractive todayWeekly Trend Recap & Reliable Intraday Trade Alerts - خودرو بانک
CEO Moves: What is Lexicon Pharmaceuticals Incs valuation compared to sectorEntry Point & Reliable Volume Spike Alerts - خودرو بانک
How volatile is Lexicon Pharmaceuticals Inc. stock2025 Market WrapUp & Weekly Return Optimization Alerts - خودرو بانک
Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Stu - GuruFocus
Lexicon Pharmaceuticals Presents Promising Phase 2b Results for Pilavapadin in Treating Diabetic Peripheral Neuropathic Pain - Quiver Quantitative
2-Point Pain Reduction: Lexicon's Non-Opioid Drug Could Be First New DPNP Treatment in 20 Years - Stock Titan
Is Vistagen Therapeutics Inc. forming a bullish divergenceTake Profit & Comprehensive Market Scan Reports - خودرو بانک
Breakouts Watch: Whats the MACD signal for Lexicon Pharmaceuticals IncJuly 2025 Short Interest & Free Risk Controlled Daily Trade Plans - خودرو بانک
Aug Update: What’s the MACD signal for NHPAPEarnings Growth Report & AI Driven Stock Price Forecasts - خودرو بانک
Lexicon Pharmaceuticals jumps amid takeover speculation - MSN
Market Outlook: What’s the RSI of Lexicon Pharmaceuticals Inc. stockRecession Risk & Real-Time Volume Triggers - khodrobank.com
Panic Selling: What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)2025 Macro Impact & Weekly Market Pulse Updates - khodrobank.com
Market Review: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaIPO Watch & Pattern Based Trade Signal System - خودرو بانک
Wall Street Recap: What is Kaltura Inc. s debt to equity ratioJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - khodrobank.com
Published on: 2025-09-16 15:08:33 - خودرو بانک
Buybacks Report: What drives Lexicon Pharmaceuticals Incs stock pricePortfolio Performance Summary & Safe Capital Growth Trade Ideas - خودرو بانک
Performance Recap: Will Lexicon Pharmaceuticals Inc benefit from sector rotationQuarterly Trade Report & Long-Term Capital Growth Ideas - خودرو بانک
Aug Movers: What is the target price for Lexicon Pharmaceuticals Inc stockTrade Risk Assessment & Technical Pattern Based Buy Signals - خودرو بانک
Institution Moves: Is Lexicon Pharmaceuticals Inc stock trending bullish2025 Momentum Check & Community Shared Stock Ideas - خودرو بانک
MACD Signal: Should I hold or sell Lexicon Pharmaceuticals Inc now2025 Historical Comparison & AI Forecast Swing Trade Picks - خودرو بانک
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - The Manila Times
Lexicon Pharmaceuticals Presents Promising Data on Pilavapadin for Diabetic Peripheral Neuropathic Pain at Upcoming Medical Meetings - Quiver Quantitative
Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming ... - nrtoday.com
Novel Non-Opioid Pain Drug Data: Lexicon's Pilavapadin Shows Promise for Diabetic Neuropathy Treatment - Stock Titan
Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating - Investing.com
Lexicon Pharmaceuticals at H.C. Wainwright: Strategic Program Updates By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at H.C. Wainwright: Strategic Program Updates - Investing.com
Lexicon submits new data to FDA for potential diabetes drug approval By Investing.com - Investing.com South Africa
Lexicon Submits Additional Benefit-Risk Data to FDA for Sotagliflozin for Type 1 Diabetes - HCPLive
Lexicon submits new data to FDA for potential diabetes drug approval - Investing.com
Lexicon submits new data to FDA supporting Zynquista's use in type 1 diabetes - MarketScreener
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):